BMC Nephrology (Mar 2018)

Successful treatment of recurrent immunoglobulin a nephropathy using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation: a case presentation

  • Haruki Katsumata,
  • Izumi Yamamoto,
  • Yo Komatsuzaki,
  • Mayuko Kawabe,
  • Yusuke Okabayashi,
  • Takafumi Yamakawa,
  • Ai Katsuma,
  • Yasuyuki Nakada,
  • Akimitsu Kobayashi,
  • Yudo Tanno,
  • Jun Miki,
  • Hiroki Yamada,
  • Ichiro Ohkido,
  • Nobuo Tsuboi,
  • Hiroyasu Yamamoto,
  • Takashi Yokoo

DOI
https://doi.org/10.1186/s12882-018-0858-9
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Both prevention and treatment of recurrent immunoglobulin A nephropathy (IgAN) in kidney transplant recipients are important since recurrent IgAN seems to affect long-term graft survival. We present here a case of recurrent IgAN that was successfully treated using steroid pulse therapy plus tonsillectomy 10 years after kidney transplantation. Case presentation A 46-year-old male was admitted for an episode biopsy with a serum creatinine level of 1.8 mg/dl and proteinuria (0.7 g/day). Histological features showed recurrent IgAN (only focal segmental mesangial proliferation) and severe arteriolar hyalinosis partly associated with calcineurin inhibitor toxicity, with limited interstitial fibrosis and tubular atrophy (5%) (IF/TA) 8 years after transplantation. Sodium restriction and conversion from cyclosporine to tacrolimus successfully reduced his proteinuria to the level of 0.15 g/day. However, 2 years later, his proteinuria increased again (1.0 g/day) and a second episode biopsy showed global mesangial proliferation with glomerular endocapillary and extracapillary proliferation accompanied by progressive IF/TA (20%). The steroid pulse therapy plus tonsillectomy successfully decreased his proteinuria and he achieved clinical remission 3 years after this treatment. Conclusion This case, presented with a review of relevant literature, demonstrates the difficulty and importance of the treatment of recurrent IgAN and calcineurin inhibitor arteriolopathy, especially in long-term kidney allograft management.

Keywords